Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,intangibleAssets,deferredLongTermLiab,goodWill,deferredLongTermAssetCharges,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,depreciation,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,epsForward,priceHint,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,HCM,428271000.0,148903008,,,-37914000,36124000,-41143000,22757000,-40443000,-63200000,-63200000,,-123000,,,,1939000,81556000,144756000,121999000,25286000,,-39853000,-41143000,808776000.0,228722000.0,428271000.0,43459000.0,693117000.0,72812000.0,27273000.0,-456742000.0,6227000.0,3425000.0,26965000.0,346133000.0,188515000.0,3425000.0,36106000.0,496230000.0,133816000.0,49939000.0,53128000.0,27451000.0,19757000.0,28636000.0,,,,,149606000.0,-2976000.0,160036000.0,-26747000.0,16035000.0,242000.0,110503000.0,-26758000.0,-430000.0,-22356000.0,15912000.0,-64000.0,-6525000.0,-231000.0,12317000.0,-6057000.0,,307715000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,40.62,1630526402,0.25999832,40.23,40.88,39.28,204555,HUTCHMED (China) Limited,NMS,PRE,0.25349626,0,False,False,0.644198,39.28 - 40.88,40.36,0.0,0.0,9,8,finmb_26652603,NasdaqGS,HUTCHMED (China) Limited,USD,433423,230828,16.949999,0.7160963,23.67 - 43.94,-3.3199997,-0.075557575,23.67,43.94,-1.065,-1.04,2,2.975,40.15914,0.4608574,0.011475778,32.40536,8.214638,6048439808,-39.057693,13.653782,15,America/New_York,EDT,-14400000,0.7,,,43.94,23.67,40.16,32.41,433.42k,230.83k,148.9M,,69.3M,1.60%,34.03%,988.49k,3.94,,0.66%,895.79k,,,,,,0.00%,,,1:1,"May 29, 2019","Dec 30, 2020","Mar 30, 2021",-58.43%,-88.14%,,-36.01%,257.96M,1.82,58.10%,-135.32M,-221.04M,-150.73M,-1.07,,396.07M,2.75,37.95M,8.17,2.63,2.97,-82.67M,,Value,Healthcare,1280,10,8,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. HUTCHMED (China) Limited has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., and Shanghai Junshi Biosciences Co. Ltd. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.",Central,852 2128 1188,1,1609372800,1622505600,10,Hong Kong,http://www.hutch-med.com,86400,10,Cheung Kong Center,852 2128 1778,Biotechnology,48th Floor 2 Queen's Road
t-1,HCM,480582000.0,148903008,,,-32237000,34833000,-38018000,16982500,-42269000,-59251500,-59251500,,-138000,,,,1398500,60605500,119857000,102874500,27014500,,-33635500,-38018000,822458000.0,205169000.0,484116000.0,12854000.0,724118000.0,72772000.0,930000.0,-415591000.0,13268000.0,4477000.0,18153000.0,235630000.0,158397000.0,4477000.0,32186000.0,530740000.0,139505000.0,202933000.0,64443000.0,27440000.0,19766000.0,31612000.0,227000.0,1171000.0,3307000.0,1515000.0,15764000.0,2791500.0,6840000.0,100045500.0,12206000.0,100296500.0,92845000.0,-26758000.0,2804500.0,-16845000.0,15912000.0,-2397000.0,-744000.0,-251000.0,7726000.0,-1945500.0,1569000.0,372343000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,40.62,1630526402,0.25999832,40.23,40.88,39.28,204555,HUTCHMED (China) Limited,NMS,PRE,0.25349626,0,False,False,0.644198,39.28 - 40.88,40.36,0.0,0.0,9,8,finmb_26652603,NasdaqGS,HUTCHMED (China) Limited,USD,433423,230828,16.949999,0.7160963,23.67 - 43.94,-3.3199997,-0.075557575,23.67,43.94,-1.065,-1.04,2,2.975,40.15914,0.4608574,0.011475778,32.40536,8.214638,6048439808,-39.057693,13.653782,15,America/New_York,EDT,-14400000,0.7,,,43.94,23.67,40.16,32.41,433.42k,230.83k,148.9M,,69.3M,1.60%,34.03%,988.49k,3.94,,0.66%,895.79k,,,,,,0.00%,,,1:1,"May 29, 2019","Dec 30, 2020","Mar 30, 2021",-58.43%,-88.14%,,-36.01%,257.96M,1.82,58.10%,-135.32M,-221.04M,-150.73M,-1.07,,396.07M,2.75,37.95M,8.17,2.63,2.97,-82.67M,,Value,Healthcare,1280,10,8,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. HUTCHMED (China) Limited has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., and Shanghai Junshi Biosciences Co. Ltd. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.",Central,852 2128 1188,1,1609372800,1622505600,10,Hong Kong,http://www.hutch-med.com,86400,10,Cheung Kong Center,852 2128 1778,Biotechnology,48th Floor 2 Queen's Road
t-2,HCM,480582000.0,148903008,,,-32237000,34833000,-38018000,16982500,-42269000,-59251500,-59251500,,-138000,,,,1398500,60605500,119857000,102874500,27014500,,-33635500,-38018000,822458000.0,205169000.0,484116000.0,12854000.0,724118000.0,72772000.0,930000.0,-415591000.0,13268000.0,4477000.0,18153000.0,235630000.0,158397000.0,4477000.0,32186000.0,530740000.0,139505000.0,202933000.0,64443000.0,27440000.0,19766000.0,31612000.0,227000.0,1171000.0,3307000.0,1515000.0,15764000.0,2791500.0,6840000.0,100045500.0,12206000.0,100296500.0,92845000.0,-26758000.0,2804500.0,-16845000.0,15912000.0,-2397000.0,-744000.0,-251000.0,7726000.0,-1945500.0,1569000.0,372343000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,40.62,1630526402,0.25999832,40.23,40.88,39.28,204555,HUTCHMED (China) Limited,NMS,PRE,0.25349626,0,False,False,0.644198,39.28 - 40.88,40.36,0.0,0.0,9,8,finmb_26652603,NasdaqGS,HUTCHMED (China) Limited,USD,433423,230828,16.949999,0.7160963,23.67 - 43.94,-3.3199997,-0.075557575,23.67,43.94,-1.065,-1.04,2,2.975,40.15914,0.4608574,0.011475778,32.40536,8.214638,6048439808,-39.057693,13.653782,15,America/New_York,EDT,-14400000,0.7,,,43.94,23.67,40.16,32.41,433.42k,230.83k,148.9M,,69.3M,1.60%,34.03%,988.49k,3.94,,0.66%,895.79k,,,,,,0.00%,,,1:1,"May 29, 2019","Dec 30, 2020","Mar 30, 2021",-58.43%,-88.14%,,-36.01%,257.96M,1.82,58.10%,-135.32M,-221.04M,-150.73M,-1.07,,396.07M,2.75,37.95M,8.17,2.63,2.97,-82.67M,,Value,Healthcare,1280,10,8,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. HUTCHMED (China) Limited has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., and Shanghai Junshi Biosciences Co. Ltd. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.",Central,852 2128 1188,1,1609372800,1622505600,10,Hong Kong,http://www.hutch-med.com,86400,10,Cheung Kong Center,852 2128 1778,Biotechnology,48th Floor 2 Queen's Road
t-3,HCM,284625000.0,148903008,,,-14381000,34833000,-16141000,12261000,-20231000,-32492000,-32492000,,-287000,,,,1045000,51570000,84062000,71801000,18111000,,-15426000,-16141000,,,288012000.0,,,,,,,,,,,,,,,,,,,,,,,,-95753000.0,-1159000.0,-97840000.0,110698000.0,-188000.0,118341000.0,11083000.0,-26758000.0,-18000.0,-1757000.0,15912000.0,-436000.0,1715000.0,-7643000.0,14452000.0,-2087000.0,1569000.0,,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,40.62,1630526402,0.25999832,40.23,40.88,39.28,204555,HUTCHMED (China) Limited,NMS,PRE,0.25349626,0,False,False,0.644198,39.28 - 40.88,40.36,0.0,0.0,9,8,finmb_26652603,NasdaqGS,HUTCHMED (China) Limited,USD,433423,230828,16.949999,0.7160963,23.67 - 43.94,-3.3199997,-0.075557575,23.67,43.94,-1.065,-1.04,2,2.975,40.15914,0.4608574,0.011475778,32.40536,8.214638,6048439808,-39.057693,13.653782,15,America/New_York,EDT,-14400000,0.7,,,43.94,23.67,40.16,32.41,433.42k,230.83k,148.9M,,69.3M,1.60%,34.03%,988.49k,3.94,,0.66%,895.79k,,,,,,0.00%,,,1:1,"May 29, 2019","Dec 30, 2020","Mar 30, 2021",-58.43%,-88.14%,,-36.01%,257.96M,1.82,58.10%,-135.32M,-221.04M,-150.73M,-1.07,,396.07M,2.75,37.95M,8.17,2.63,2.97,-82.67M,,Value,Healthcare,1280,10,8,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. HUTCHMED (China) Limited has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., and Shanghai Junshi Biosciences Co. Ltd. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.",Central,852 2128 1188,1,1609372800,1622505600,10,Hong Kong,http://www.hutch-med.com,86400,10,Cheung Kong Center,852 2128 1778,Biotechnology,48th Floor 2 Queen's Road
